keyword
https://read.qxmd.com/read/23954314/validation-of-endoscopic-activity-scores-in-patients-with-crohn-s-disease-based-on-a-post-hoc-analysis-of-data-from-sonic
#21
RANDOMIZED CONTROLLED TRIAL
Marc Ferrante, Jean-Frederic Colombel, William J Sandborn, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert R D'Haens, Christien J van der Woude, Silvio Danese, Robert H Diamond, Alessandra Faria Oortwijn, Kezhen L Tang, Michael Miller, Freddy Cornillie, Paul J Rutgeerts
BACKGROUND & AIMS: Mucosal healing might alter midterm and long-term outcomes of patients with Crohn's disease (CD) and has become an important end point in clinical trials. However, the minimal degree of mucosal improvement (endoscopic response) required to alter midterm outcomes is not known. We aimed to determine the best definition of endoscopic response by evaluating data on the Simple Endoscopic Score for Crohn's Disease (SES-CD) and the Crohn's Disease Endoscopic Index of Severity (CDEIS) from the Study of Biologic and Immunomodulator Naive Patients in Crohn's Disease (SONIC trial)...
November 2013: Gastroenterology
https://read.qxmd.com/read/23037784/an-alternative-technique-using-a-gutta-percha-points-and-blue-methylene-to-excision-of-congenital-fistula-of-lower-lip-in-patient-with-van-der-woude-syndrome
#22
JOURNAL ARTICLE
Carlos Henrique Castro, Matheus Furtado De Carvalho, Debora Cury Veloso, Marcio De Moraes
Van der Woude syndrome is a rare disorder of craniofacial development, characterized by the triad (congenital lip fistula, cleft lip and/or cleft palate). Discomfort caused by spontaneous or induced drainage of saliva/mucus when pressure is applied or during a meal as well as poor aesthetics match is one of the main complaints of patients with congenital lip fistula. This paper aims to describe an alternative technique for excision of the congenital fistula of lower lip in patient with Van der Woude syndrome, using gutta percha points and methylene blue for better identify the the fullest extent of the fistula...
2012: Stomatologija
https://read.qxmd.com/read/22535619/increased-suppressor-of-cytokine-signaling-3-expression-predicts-mucosal-relapse-in-ulcerative-colitis
#23
JOURNAL ARTICLE
Yi Li, Veerle J A A Nuij, Judith E Baars, Katharina Biermann, Ernst J Kuipers, Maikel P Peppelenbosch, Colin de Haar, C Janneke van der Woude
BACKGROUND: Most biomarkers predicting mucosal relapse of ulcerative colitis (UC) patients in clinical remission represent low levels of mucosal inflammation. Since SOCS3 expression may increase the vulnerability of intestinal epithelial cells (IECs) to various insults, we investigated whether its expression predicts mucosal relapse in UC patients in clinical remission without any signs of mucosal inflammation. METHODS: UC patients (n = 32) in clinical, endoscopic, and histological remission were followed up for 9 years...
January 2013: Inflammatory Bowel Diseases
https://read.qxmd.com/read/22325181/recommendations-for-the-treatment-of-ulcerative-colitis-with-infliximab-a-gastroenterology-expert-group-consensus
#24
JOURNAL ARTICLE
Walter Reinisch, Gert Van Assche, Ragnar Befrits, William Connell, Geert D'Haens, Subrata Ghosh, Pierre Michetti, Thomas Ochsenkühn, Remo Panaccione, Stefan Schreiber, Mark S Silverberg, Dario Sorrentino, C Janneke van der Woude, Séverine Vermeire, Julian Panes
BACKGROUND AND AIMS: Infliximab is currently the only biologic approved for treatment of adults with moderate to severe, active ulcerative colitis (UC) unresponsive to conventional therapies. It rapidly controls symptoms, induces and sustains steroid-free remission, stimulates mucosal healing, and reduces serious complications. Although infliximab tends to be reserved for patients with severe disease, it may be even more beneficial for moderate disease earlier in the disease course. Therefore, it is important to identify which patients are candidates for infliximab therapy...
March 2012: Journal of Crohn's & Colitis
https://read.qxmd.com/read/22261537/physician-perspectives-on-unresolved-issues-in-the-use-of-conventional-therapy-in-crohn-s-disease-results-from-an-international-survey-and-discussion-programme
#25
JOURNAL ARTICLE
Marc Ferrante, Konstantinos Karmiris, Evan Newnham, Jesse Siffledeen, Zuzana Zelinkova, Gert van Assche, Peter L Lakatos, Julian Panés, Andreas Sturm, Simon Travis, C Janneke van der Woude, Walter Reinisch, Jean-Frédéric Colombel, Remo Panaccione
BACKGROUND AND AIMS: Data on the optimal use of conventional therapies in Crohn's disease are lacking in guidelines. An educational programme was established to explore questions raised in clinical practice and to provide practical answers. METHODS: Telephone interviews with 96 gastroenterologists and a web survey of 1370 gastroenterologists identified 26 key questions. Ten questions were taken forward to the next stage based on the opinion of an International Steering Committee...
February 2012: Journal of Crohn's & Colitis
https://read.qxmd.com/read/22038857/recommendations-for-the-treatment-of-crohn-s-disease-with-tumor-necrosis-factor-antagonists-an-expert-consensus-report
#26
JOURNAL ARTICLE
Brian G Feagan, Marc Lémann, Ragnar Befrits, William Connell, Geert D'Haens, Subrata Ghosh, Pierre Michetti, Thomas Ochsenkühn, Remo Panaccione, Stefan Schreiber, Mark Silverberg, Dario Sorrentino, C Janneke van der Woude, Severine Vermeire, Paul Rutgeerts
BACKGROUND: Symptom relief is the traditional treatment goal in Crohn's disease (CD). New goals including mucosal healing and bowel preservation are now achievable with tumor necrosis factor (TNF) antagonists. Infliximab and adalimumab are approved as second-line treatments for severe, active CD. Certolizumab pegol is approved only in the U.S. and Switzerland as second-line treatment for moderate-to-severe, active CD. Data from trials of infliximab suggest that high-risk patients and patients with active inflammation (CRP elevation and/or ileocolonic ulcers) may benefit from earlier use of this drug...
January 2012: Inflammatory Bowel Diseases
https://read.qxmd.com/read/21615435/review-article-defining-remission-in-ulcerative-colitis
#27
REVIEW
S P L Travis, P D R Higgins, T Orchard, C J Van Der Woude, R Panaccione, A Bitton, C O'Morain, J Panés, A Sturm, W Reinisch, M A Kamm, G D'Haens
BACKGROUND: There is no international agreement on scoring systems used to measure disease activity in ulcerative colitis, nor is there a validated definition for disease remission. AIM: To review the principles and components for defining remission in ulcerative colitis and propose a definition that will help improve patient outcomes. METHODS: A review of current standards of remission from the perspective of clinical trials, guidelines, clinical practice and patients was conducted by the authors...
July 2011: Alimentary Pharmacology & Therapeutics
https://read.qxmd.com/read/20856020/wound-complications-after-cleft-repair-in-children-with-van-der-woude-syndrome
#28
JOURNAL ARTICLE
Jodi L P Jones, John W Canady, James T Brookes, George L Wehby, Jamie L'Heureux, Brian C Schutte, Jeffrey C Murray, Martine Dunnwald
Van der Woude syndrome (VWS; OMIM 119300) is an autosomal-dominant condition associated with clefts of the lip and/or palate and lower lip pits and is caused by mutations in interferon regulatory factor 6 (IRF6). The standard of practice for children born with cleft lip/palate is surgical repair, which requires proper wound healing. We tested the hypothesis that children with VWS are more likely to have wound complications after cleft repair than children with nonsyndromic cleft lip/palate (NSCLP). Furthermore, we hypothesized that children with VWS have more surgical procedures...
September 2010: Journal of Craniofacial Surgery
https://read.qxmd.com/read/20393175/infliximab-azathioprine-or-combination-therapy-for-crohn-s-disease
#29
RANDOMIZED CONTROLLED TRIAL
Jean Frédéric Colombel, William J Sandborn, Walter Reinisch, Gerassimos J Mantzaris, Asher Kornbluth, Daniel Rachmilewitz, Simon Lichtiger, Geert D'Haens, Robert H Diamond, Delma L Broussard, Kezhen L Tang, C Janneke van der Woude, Paul Rutgeerts
BACKGROUND: The comparative efficacy and safety of infliximab and azathioprine therapy alone or in combination for Crohn's disease are unknown. METHODS: In this randomized, double-blind trial, we evaluated the efficacy of infliximab monotherapy, azathioprine monotherapy, and the two drugs combined in 508 adults with moderate-to-severe Crohn's disease who had not undergone previous immunosuppressive or biologic therapy. Patients were randomly assigned to receive an intravenous infusion of 5 mg of infliximab per kilogram of body weight at weeks 0, 2, and 6 and then every 8 weeks plus daily oral placebo capsules; 2...
April 15, 2010: New England Journal of Medicine
https://read.qxmd.com/read/17696821/biologics-in-crohn-s-disease-searching-indicators-for-outcome
#30
REVIEW
C Janneke van der Woude, Daniel W Hommes
New insights into the underlying mechanism of Crohn's disease is enabling the development of new therapies. Even though the mechanisms of these drugs have been studied extensively, reliable indicators for implementation of new biologic drugs are still needed. This review presents biologics in Crohn's disease focusing on efficacy, steroid sparing, mucosal healing and safety, including immunogenicity.
August 2007: Expert Opinion on Biological Therapy
https://read.qxmd.com/read/15122328/overexpression-of-sprouty-2-inhibits-hgf-sf-mediated-cell-growth-invasion-migration-and-cytokinesis
#31
JOURNAL ARTICLE
Chong-Chou Lee, Andrew J Putnam, Cindy K Miranti, Margaret Gustafson, Ling-Mei Wang, George F Vande Woude, Chong-Feng Gao
A strict regulation of hepatocyte growth factor/scatter factor (HGF/SF)-Met signaling is essential for its appropriate function. Several negative regulators of Met signaling have been identified. Here we report that human Spry2 is induced by HGF/SF and negatively regulates HGF/SF-Met signaling. We show that overexpression of Spry2 inhibits cell proliferation, anchorage-independent cell growth, and migration in wound-healing and in vitro invasion assays. Measured in an electric cell-substrate impedance sensing biosensor, cell movement is restricted, because Spry2 dramatically facilitates cell attachment and spreading by enhancing focal adhesions and increasing stress fibers...
July 1, 2004: Oncogene
1
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.